Skip to content
Project Directory
  • Français
Donate Now
  • Français
  • About
    • What We Do
    • Leadership
    • Team
    • Publications
    • Careers
  • Diseases/Disorders
    • One Brain
    • ALS
    • Alzheimer’s
    • Autism
    • Brain Cancer
    • Brain Injury
    • Epilepsy
    • Mental Illness
    • Multiple Sclerosis
    • Parkinson’s
    • Stroke
    • Other
  • Research
    • Programs
    • Funding Opportunities
    • Program Partners
    • Announcements
  • Impact
  • Ways To Give
    • Your Impact
    • How You Can Help
    • Events

Funded Grants

Back to results

Testing therapeutic approaches to improve cognitive dysfunction in a primate model of Alzheimer’s Disease

Project Overview

Alzheimer’s Disease (AD) is a severe dementia that is likely a result of years of buildup in the brain of molecules called amyloid-beta oligomers (AβOs). The pursuit of new disease-modifying therapeutics for AD that change the natural progression of AD early in its course is under intense investigation. A major impediment, however, lies in the difficulty of translating therapies that work in animals (usually rodents) to the specific human disease condition. Thus, the main goal of this proposal is to investigate how injection of AβOs in the non-human primate (NHP) brain leads to changes in brain function, expression of early biomarkers of disease, and eventually brain pathology as well as changes in behaviour and cognition. We injected AβOs into the lateral ventricles of adult macaque monkeys and found that this can trigger a pathology in neurons that mimics several attributes of AD. The second main goal of this proposal is to explore two novel neurosurgical approaches that are designed to promote rescue of nerve cells and their connections by implanting trophic molecules and using deep brain stimulation to promote regrowth and plasticity to overcome the damage induced by the AβOs. Thus, the primary goal of this grant is to first establish and track in vivo the impact of AβOs in the NHP brain and determine if they trigger pathological features that resemble the hallmarks of AD. Secondly, we will examine therapeutic strategies to promote regrowth and plasticity. The expected outcome of the proposed studies is the identification of a strategy that could ultimately have profound effects by slowing AD progression and interrupting the onset of AD.

Principal Investigator

Douglas Munoz , Queen’s University

Team Members

Stephen Scott, Queen’s University

Douglas Cook, Queen’s University

Ron Levy, Queen’s University

Partners and Donors

Queen's University

Project Ongoing

Testing therapeutic approaches to improve cognitive dysfunction in a primate model of Alzheimer’s Disease

  • Program Type

    Team grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    2015 MIRI Team Grants

  • Province

    Ontario

  • Start Date

    2016

  • Total Grant Amount

    $857,062

  • Health Canada Contribution

    $428,531

Contact Us

1200 McGill College Avenue
Suite 1600, Montreal, Quebec
H3B 4G7

The offices of Brain Canada Foundation are located on the traditional, ancestral territory of the Kanien'kehá:ka Peoples, a place which has long served as a site of meeting and exchange amongst nations.

+1 (514) 989-2989 info@braincanada.ca

Playing with Marbles Podcast

Join us and take a journey to the real last great frontier – the brain.

Listen

Subscribe to Brain News

Receive our monthly electronic newsletter with updates on funded projects, upcoming events and breakthroughs in brain research.

Sign up

© 2023 Brain Canada Foundation

Registration number: 89105 2094 RR0001

  • Terms and Conditions
  • Privacy Policy

Design by Field Trip & Co